WMS 2025 Summary Programme

Version: 06/10/25

Monday 6th October 2025

08:30-19:00	**Pre-Congress Teaching Course** (separate registration required) *-2.41/-2.42*

Tuesday 7th October 2025

08:30-11:30	**Pre-Congress Teaching Course** (separate registration required) *- 2.33 and - 2.32*	
10:00-15:00	**WMS Executive Board Meeting** (by invitation only) *-2.41/-2.42*	
13:30-18:00	**Registration, welcome refreshments and poster set up** *Foyer D, and Hall X1*	
15:30 -16:30	**Regional Networking Reception** *Hall G*	
16:30-17:30	**Industry Symposium 1 (withdrawn)** *Hall G*	**Industry Symposium 2** *Hall K*
18:00-18:45	**Opening Ceremony** *Hall D*	
18:45-21:00	**Networking Reception** *Hall X1*	

Wednesday 8th October 2025

07:15-19:30	**Congress desk open** *Foyer D*	
07:45-08:45	**Industry Symposium 3** *Hall G*	**Industry Symposium 4** *Hall K*
08:50-09:30	**Congress Welcome -** Message from the President *Hall D*	
09:30-11:00	**Topic 1: Neuromuscular diseases as multisystemic disorders** *Hall D* *Supported by the EAN* *Moderators: Günther Bernert, Klinik Favoriten, Austria & Corinne Horlings, Medical University Innsbruck, Austria* 09:30-10:00 **01INV** How can proteomics help to elucidate the pathophysiology crosstalk in muscular dystrophy and associated multi-system dysfunction? *Kay Ohlendieck, National University of Ireland* 10:00-10:30 **02INV** Beyond muscular dystrophies: roles of MD-related proteins in different organ systems *Lilli Winter, Medical University of Vienna, Austria* 10:30-10:45 **01O** Interferon-γ causes myogenic cell dysfunction and senescence in immune myopathies *Francois Jerome Authier, Paris Est Creteil University, France* 10:45-11:00 **02O** Brachio-cervical inflammatory myopathy: Evidence for a distinct form of inflammatory muscle disease *Felix Kleefeld, Bg Universitätklinikum Bergmannsheil, Germany*	
11:00-11:30	**Morning refreshments, exhibition and poster viewing** *Hall X1*	
11:00-11:30	**Myology Café** Myology Developments Across the World and Guidelines Committees *Hall X1*	
11:30-13:30	**Topic 1: Neuromuscular diseases as multisystemic disorders** (continued) *Hall D* *Moderators: John Vissing, University of Copenhagen, Denmark & Jana Haberlová, University Hospital Motol, Czechia*	

	11:30-12:00 03INV Myotonic Dystrophy Type 1: A multisystemic disorder with remarkable clinical variability and burden *Hilde Braakman, Amalia Children's Hospital, Radboud University Medical Center, the Netherlands* **12:00-12:30 04INV** Spinal Muscular Atrophy: Systemic Disease, Focal Treatment – or Vice Versa? *Janbernd Kirschner, University of Freiburg, Germany* **12:30-12:45 03O** Cognitive development in children with 5q-SMA identified by neonatal screening – four years follow-up *Hieke Kölbel, Universitätsmedizin Essen, Germany* **12:45-13:00 04O** Denervated human muscle fibers promote reinnervation via neurotrophic factor release in SMA and ALS *Jordi-Diaz Manera, Newcastle University, United Kingdom* **13:00-13:15 05O** Redefining triple A syndrome: A multinational study of the neuromuscular phenotype in the largest genetically confirmed cohort to date *Menekse Oeztuerk, BG University Hospital Bergmannsheil Bochum, Germany* **13:15-13:30 06O** In-depth examination of motor endplate pathology in AChR-Ab-positive myasthenia gravis *Corinna Preusse, Charité-Universitätsmedizin Berlin, Germany*
13:30-14:30	**Lunch, exhibition and poster viewing** *Hall X1*
13:45-14:30	**NMD Editorial Board Meeting** (by invitation only) *-2.41/-2.42*
14:30-15:30	**Poster session 1** *Hall X1* **01P-20P, 22P-50P, 51VP, 52P, 53VP-55VP: Acquired, inflammatory, myositis** **166P-192P: DMD – imaging and outcome measures** **298P-313P: Muscle MRI & new imaging techniques** **399P-426P, 427VP-430VP: Clinical trials, access to health care and outcome measures** **505P-528P, 529VP, 530P-536P, 537VP: SMA clinical** **651P-677P, 678VP-688VP: DMD - treatments**
15:30-16:00	**Short Oral Presentations 1** *K1* **Updates on SMA and DMD trials** **426P, 423P, 422P, 425P, 424P** *Moderator: Ulrike Schara-Schmidt, University Duisburg-Essen, Germany* **Short Oral Presentations 2** *K2* **Inflammatory myopathies** **48P, 46P, 49P, 24P, 50P** *Moderator: Georgio Tasca, Newcastle University, United Kingdom* **Short Oral Presentations 3** *-2.93/-2.94* **Novel discoveries in SMA, DMD and ADSS1 myopathy** **534P, 536P, 535P, 192P, 191P, 313P** *Moderator: Simone Mahal, Favoriten Hospital, Austria*
16:15-17:00	**Congress Debate** *Hall D* **Should families be offered n=1 treatments?** *Moderators: Michelle Lorentzos, The Sydney Children's Hospitals Network, Australia & Jorge A Bevilacqua, Universidad de Chile, Chile* **13INV** *Annemieke Aartsma-Rus, Leiden University Medical Center, the Netherlands* **14INV** *Kevin Flanigan, Nationwide Children's Hospital, United States of America* The WMS Congress Debate has quickly become one of the most popular elements of the scientific programme. This year the debate will ask the timely question, should we be providing hyper-individualised therapies/treatments, namely n=1 or n=few, to patients with neuromuscular disease? Many genetic neuromuscular patients live with progressive or even fatal conditions that lack effective treatment options. In an age that enables the design of a single, tailor-made antisense oligonucleotide (ASO) or gene therapy for a single patient, or a very small group of patients, where should we draw the line? When families request a bespoke therapy for their loved one, should we allow unproven, individualised treatments outside traditional clinical trials? Is this compassion... or chaos in the making? *continued on next page*

	The debate team includes experts from across the globe, including opponents Kevin Flanagan (USA) who will argue in favour of providing hyper-individualised therapies and Annemieke Aartsma-Rus (The Netherlands), who will be arguing against, with expert moderation by Michelle Lorentzos (Australia) and Jorge Bevilacqua (Chile). Please note that in an effort to demonstrate differing viewpoints, as well as educate and entertain, Kevin and Annemieke will intentionally present extreme positions that may not convey their actual and nuanced perspectives on this important issue. To round off this interactive discussion, the debaters will offer their genuine reflections on the future of individualised treatments, and present their insights regarding the real-world complexities. We encourage members of the audience to participate. Please join us for what we are sure will be another Congress highlight!
17:15-18:15	**Poster session 2** *Hall X1* **118P-165P:** CM – CMD **193P-217P:** FSHD **314P-329P:** Multidisciplinary management of neuromuscular diseases **431P-456P, 457VP-458VP:** Genetics of NMD (new genes and NGS, diagnostic etc.) **486P-503P, 504VP:** LGMD **551P-566P:** EDMD, OPDM, autophagic, extramuscular

18:15-18:45	**Short Oral Presentations 4** *K1* **Genetic neuromuscular disorders 1** **451P, 453P, 454P, 128P, 452P, 161P** *Moderator: Wolfgang Löscher, Medical University Innsbruck, Austria*	**Short Oral Presentations 5** *K2* **Genetic neuromuscular disorders 2** **163P, 165P, 164P, 456P, 455P, 502P** *Moderator: Hacer Durmus, Istanbul Faculty of Medicine, Turkey*	**Short Oral Presentations 6** *-2.93/-2.94* **FSHD** **216P, 214P, 217P, 215P** *Moderator: Carmen Paradas, Hospital Universitario Virgen del Rocío/IBiS, Spain*
19:00-20:00	**Industry Symposium 5** *Hall G*	**Industry Symposium 6** *Hall D*	

Thursday 9th October 2025

07:00-15:00	**Congress desk open** *Foyer D*
07:45-09:15	**Interesting Case Discussions** *Hall D* *Moderators: Teerin Liewluck, Mayo Clinic Rochester, United States of America & Ana Ferreiro, Institut De Myologie, France* **Case 1:** Atypical nemaline myopathy *Pascal Laforet, Hopital Raymond-Poincaré APHP, France* **Case 2:** A diagnostic odyssey solved by discovering a novel Alu insertion in the TTN gene *Aysylu Murtazina, Research Centre for Medical Genetics, Russia* **Case 3:** Recessive variants in DNAJB4 cause a distinct protein aggregate myopathy with early respiratory involvement *Jonathan DeWinter, University Hospital Antwerp, Belgium* **Case 4:** The overlapping landscape of neuromuscular disorders in the era of NGS: lessons learned from a family with autosomal dominant scapuloperoneal motor weakness *Gorka Fernandez Garcia de Eulate, Association Institut De Myologie, France* **Case 5:** A novel mutation of HSPB8 causing atypical pediatric-onset axial and limb-girdle involvement *Xiaoqing Lyu, Qilu Hospital of Shandong University, China*

	Case 6: Anti-neurofascin-155 nodopathy in a 12-year-old girl *Femke Klouwer, Leiden University Medical Center, The Netherlands* **Case 7:** Severe osteochondral complications in NTRK1-related CIPA: A case report and mechanistic insights *Sophelia Chan, The University of Hong Kong, Hong Kong* **Case 8:** Myofibrillar Myopathy cases with equinovarus deformity and early contractures *Hacer Durmus Tekce, İstanbul Üniversitesi Tıp Fakültesi Hastanesi, Turkey*
09:30-11:00	**Topic 2: Multidisciplinary management of neuromuscular diseases** *Hall D* *Nicol Voermans, Radboud University Medical Centre, the Netherlands & Payam Mohassel, Johns Hopkins University, United States of America* **09:30-10:00 05INV** Psychological care in neuromuscular diseases: supporting patients with rare, progressive, and genetic diseases in the era of gene therapy *Sabrina Sayah, Université de Nantes, France* **10:00-10:30 06INV** The expanding role of rehabilitation in neuromuscular diseases: from care to translational research *Cynthia Gagnon, Université de Sherbroooke, Canada* **10:30-10:45 07O** Neuropsychiatric burden of Dystrophinopathies: A multi-centre European study *Anna Kolesnik, Great Ormond Street Hospital, University College London, United Kingdom* **10:45-11:00 08O** Insights into the use of the capability approach in multidisciplinary rehabilitation for persons with neuromuscular diseases *Eirlys Pijpers, Radboud University Medical Center, the Netherlands*
11:00-11:30	**Morning refreshments, exhibition and poster viewing** *Hall X1*
11:00-11:30	**Myology Café** Environmental Sustainability Committee *Hall X1*
11:30-13:30	**Topic 2: Multidisciplinary management of neuromuscular diseases** (continued) *Hall D* *Moderators: Nicol Voermans, Radboud University Medical Centre, the Netherlands & Payam Mohassel, Johns Hopkins University, United States of America* **11:30-12:00 07INV** Coordination of care for people with neuromuscular diseases: the sum is greater than the individual parts *Ros Quinlivan, University College London, United Kingdom* **12:00-12:30 08INV** Palliative care for adults with neuromuscular diseases- what do we know and where next? *Derek Willis, the Severn Hospice, United Kingdom* **12:30-12:45 09O** Optimising transition and advanced care planning for young people with neuromuscular disorders *Kathryn Irving, Royal Children's Hospital Melbourne, Australia* **12:45-13:00 10O** Sexual and pelvic floor function in women with Muscular Dystrophy *Johanna I Hamel, University of Rochester, United States of America* **13:00-13:15 11O** Heart transplantation in males with dystrophinopathy: An advanced cardiac therapies improving outcomes network (ACTION) Dystrophinopathy registry analysis *Emily Hayes, Nationwide Children's Hospital, United States of America* **13:15-13:30 12O** Computational models for new patient stratification strategies of neuromuscular disorders (CoMPaSS-NMD): a new strategy to tackle hereditary neuromuscular diseases *Andi Nuredini, University of Modena and Reggio Emilia, Italy*
13:30-14:45	**Lunch, exhibition and poster viewing** *Hall X1*
13:45-14:45	**WMS 2025 Early to Mid-Career Peer Networking Session** (separate registration required) *Hall G* *Moderators: Megan Iammarino, Nationwide Children's Hospital, United States of America & Jordi Diaz-Manera, Newcastle University, United Kingdom*

	For the first time in its history, in October 2025 the WMS membership will elect a dedicated early to mid-career member representative to the Executive Board. This session is a unique opportunity for early to mid-career delegates to meet the newly-elected WMS Board representative and to collaborate with fellow early-mid career attendees to shape future activities within the WMS and the WMS Congress. This is a unique opportunity for participants to have their say in early to mid-career focussed content at future WMS Congresses, journal content, and WMS activities. Session attendees will also gain access to a valuable international professional peer network, providing opportunities for future collaborations, sharing expertise, and career development.
15:00-17:30	**Poster viewing/group activity** (separate registration required)
17:30-20:00	**Group Activity Networking Reception** (separate registration required)

Friday 10th October 2025

08:00-18:00	**Congress desk open** *Foyer D*
08:30-10:15	**Topic 3: Advances in therapies and drug development** *Hall D* *Supported by the ICNMD* *Moderators: Elie Naddaf, the Mayo Clinic, United States of America & Nalini Atchayaram, National Institute of Mental Health and Neuro Sciences, India* **08:30-09:00 09INV** Advances in therapies and drug development: improving AAV Vectors for Neuromuscular Disease indications *Melissa Spencer, Center for Duchenne Muscular Dystrophy at UCLA, United States of America* **09:00-09:30 10INV** AAV transduction optimization for NMD *Oumeya Adjali, Université de Nantes, France* **09:30-09:45 13O** Identifying naturally occurring adeno-associated virus serotypes that transduce mouse skeletal muscles fibro-adipogenic progenitors in vivo *Fady Guirguis, University College London, United Kingdom* **09:45-10:00 14O** Regulatory T cells suppress dystrophin immunity *Philip Farahat, University of California Irvine, United Sates of America* **10:00-10:15 15O** Towards a human multi-organoid platform to develop and assess specificity, toxicity and efficacy of neuromuscular gene therapies *Francesco Saverio Tedesco, University College London, Great Ormond Street Hospital & The Francis Crick Institute, United Kingdom*
10:15-10:45	**Morning refreshments, exhibition and poster viewing** *Hall X1*
10:15-10:45	**Myology Café** Featured Cases and EDI Committees *Hall X1*
10:45-12:30	**Topic 3: Advances in therapies and drug development** (continued) *Hall D* *Moderators: Ana Tesi Rocha, Stanford University, United States of America & Vishnu Venugopalan Yamuna, All India Institute of Medical Sciences, India* **10:45-11:15 11INV** Leveraging the muscle fusogens for gene delivery *Douglas Millay, Cincinnati Children's Hospital, United States of America* **11:15-11:45 12INV** Innovation in nanoparticles as drug delivery vehicles for the treatment of muscle disorders *Heather Lau, Yale School of Medicine, United States of America*

	11:45-12:00 16O Calcitriol ameliorates myotonia in 3D DM1 skeletal muscle models via a MBNL1-independent mechanism *Juan Manuel Fernández Costa, Institute For Bioengineering of Catalonia, Spain* **12:00-12:15 17O** Collagen type VI regulates TGFβ bioavailability in skeletal muscle in mice *Payam Mohassel, Johns Hopkins University, United States of America* **12:15-12:30 18O** Translation of GGC repeat expansions into a toxic polyG protein in oculopharyngodistal myopathy 2 *Kexin Jiao, Huashan hospital, Fudan University, China*		
13:00-14:00	**WMS General Assembly/poster viewing for non-members** *Hall D*		
12:30-14:00	**Lunch, exhibition and poster viewing** *Hall X1*		
13:45-14:15	**Sponsor meeting** (by invitation only) *-2.41/-2.42*		
14:15-15:15	**Poster Session 3** *Hall X1* **56P-89P: Advances in therapies and drug development** **104P-116P, 117VP: Cell insights, muscle homeostasis** **251P-296P, 297VP: Dystrophinopathies (animals models, biomarkers, brain, genetics)** **366P-398P: Myotonic dystrophy** **538P-550P: Registries, networks and care of NMD** **589P-609P: SMA outcome measures and registries** **689P, 690VP, 691P-702P: Distal myopathies, MFM**		
15:15-15:45	**Short Oral Presentations 7** *K1* **Myotonic dystrophy and distal myopathies** **689P, 395P-398P** *Moderator: Benedikt Schoser, Friedrich-Baur-Institut LMU München, Germany*	**Short Oral Presentations 8** *K2* **Advances in therapies and SMA** **609P, 87P, 88P, 116P, 86P** *Moderator: Wenhua Zhu, Huashan Hospital, Fudan University, China*	**Short Oral Presentations 9** *-2.93/-2.94* **Insights into muscular dystrophy** **288P, 89P, 270P, 295P** *Moderator: Sophelia Chan, The University of Hong Kong, China*
15:45-16:45	**Poster Session 4** *Hall X1* **90P-103P: ALS/neuropathy** **218P-250P: Neuromuscular diseases as multisystemic disorders** **330P-365P: Metabolic and mitochondrial myopathies** **459P-484P, 485VP: Myasthenia Gravis, NMJ1-2, periodic paralysis** **567P-569P, 571P-574P: Pompe disease** **575P-588P: SMA therapies** **610P-620P, 621VP, 622P-648P, 649VP-650VP: DMD - clinical care and cases reports, BMD** **704LBP-712LBP, 714LBP-719LBP, 721LBP-728LBP, 730LBP-734LBP: Late breaking** **735VSP-743VSP: Environmental Sustainability**		
16:45-17:15	**Short Oral Presentations 10** *K1* **Multisystemic disorders and disease mechanisms** **647P, 648P, 246P -248P** *Moderator: Mridul Johari, The Harry Perkins Institute of Medical Research, Australia*	**Short Oral Presentations 11** *K2* **Metabolic and mitochondrial disorders** **361P - 365P** *Moderator: Suur Biliciler, Ut Health Science Center at Houston, Mcgovern Medical School, United States of America*	**Short Oral Presentations 12** *-2.93/-2.94* **Congenital muscle diseases** **471P, 249P, 484P, 250P** *Moderator: Hernán Gonorazky, The Hospital for Sick Children, Canada*
19:15-01:00	**Networking Dinner** (separate registration required)		

Saturday 11th October 2025

07:15	**Congress desk open** *Foyer D*
07:30-09:00	**Clinical Trial Updates** *Hall D* *Moderators: Ann Agnes Mathew, Bangalore Baptist Hospital, India & Tobias Ruck, University Hospital Bochum, Germany* **07:30-07:45 19O** **07:45-08:00 20O** **08:00-08:15 21O** **08:15-08:30 22O** **08:30-08:45 23O** **08:45-09:00 24O**
09:00-09:15	**Comfort break**
09:15-09:45	**Victor Dubowitz Lecture** *Hall D* Myology in Asia *Ichizo Nishino, National Institute of Neuroscience, NCNP, Japan* *Moderators: Volker Straub, Newcastle University, United Kingdom & Gina Ravenscroft The Harry Perkins Institute of Medical Research, Australia*
09:45-11:15	**Poster Highlights** *Moderators: Matthias Baumann, Medical University Innsbruck, Austria & Rotem Orbach, National Institutes of Health, United States of America* **09:45-10:00 30O** Expert consensus on gene therapy for spinal muscular atrophy with onasemnogene abeparvovec: treatment decision, administration and patient follow-up *Jean Baptiste Davion, French Reference Center for Neuromuscular Diseases, Lille University Hospital Center, France* **10:00-10:15 26O** C2C12-CTE – a versatile myotube model for C-terminal titin studies *Jaako Sarparanta, Folkhälsan Research Center, Helsinki, Finland* **10:15-10:30 27O** Heart rate and ventilation during submaximal cycling exercise as physiological outcome measures in Duchenne muscular dystrophy *Tanja Taivassalo, University Of Florida, Gainesville, United States* **10:30-10:45 28O** Evaluating oxygen saturation and recovery dynamics in skeletal muscle during exercise in adults with spinal muscular atrophy *Tina Duong, Stanford University, Palo Alto, United States* **10:45-11:00 29O** A closer look at the contribution of fibro-adipogenic precursors in the pathomechanism of autoimmune myositis: correlating transcriptomics with muscle pathology *Francia Victoria De Los Reyes, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira,Tokyo, Japan* **11:00-11:15 25O** ASCC3-related congenital myopathy is linked to a defect in ribosome-associated quality control *Marion Onnée, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil, INSERM U955, Créteil, France*
11:15-11:45	**Morning refreshments, exhibition and poster viewing** *Hall X1*
11:45-13:15	**Late Breaking News** *Hall D* *Moderators: Hanns Lochmuller, Children's Hospital of Eastern Ontario Institute, Canada & Sandra Donkervoort, National Institutes of Health, United States of America* **11:45-11:57 01LBO** A novel 5' UTR CCG expansion in TBC1D7 causes Oculopharyngodistal myopathy *Liedewei Van De Vondel, University of Miami Miller School of Medicine, Miami, United States*

	11:57-12:09 02LBO DUX4-induced toxicity in Facioscapulohumeral muscular dystrophy requires mitochondrial respiratory chain function *Peter Zammit, King's College London,United Kingdom* **12:09-12:21 03LBO** Opposite modulation of dynamin and amphiphysin provides therapeutic proof-of-concepts for a peripheral neuropathy and two congenital myopathies *Jocelyn Laporte, GBMC, Illkirch, France* **12:21-12:33 04LBO** In utero risdiplam for severe SMA: a case series *Richard Finkel, St. Jude Children's Research Hospital, Memphis, United States* **12:33-12:45 05LBO** Delpacibart zotadirsen (del-zota) showed trends toward improvement in functional and patient-reported outcomes in individuals with DMD amenable to exon 44 skipping *Kevin Flanigan,Nationwide Children's Research Institute, Columbus, United States* **12:45-12:57 06LBO** Acute liver injury mitigation and management in patients with Duchenne muscular dystrophy following administration of delandistrogene moxeparvovec: expert considerations *Perry Shieh, University of California Los Angeles, Los Angeles, United States* **12:57-13:09 07LBO** Safety and preliminary efficacy is demonstrated in a phase 1/2a clinical trial of AJ201 in spinal and bulbar muscular atrophy *Christopher Grunseich, National Institutes of Health, Bethesda, United States*
13:15-13:45	**Prize Giving Ceremony** *Hall D* *Moderator: Marco Savarese, University of Helsinki, Finland* **Introduction to the WMS 2026 Congress, Hiroshima, Japan** **Handover of the WMS flag and close of the Congress**
13:45-14:30	**Homeward lunch**